PMID- 35932165
OWN - NLM
STAT- MEDLINE
DCOM- 20220901
LR  - 20220906
IS  - 1753-0407 (Electronic)
IS  - 1753-0393 (Print)
IS  - 1753-0407 (Linking)
VI  - 14
IP  - 8
DP  - 2022 Aug
TI  - Cilostazol treatment for preventing adverse cardiovascular events in patients 
      with type 2 diabetes and coronary atherosclerosis: Long-term follow-up of the 
      ESCAPE study.
PG  - 524-531
LID - 10.1111/1753-0407.13300 [doi]
AB  - BACKGROUND: Previously, in the ESCAPE study, a randomized controlled trial, we 
      found that 12 months of cilostazol administration significantly decreased 
      coronary artery stenosis and the noncalcified plaque component compared with 
      aspirin. The goal of the current study was to evaluate the effect of cilostazol 
      treatment on cardiovascular events up to 7 years after the end of the original 
      study. METHODS: After the end of the ESCAPE study with patients with type 2 
      diabetes mellitus (T2DM) and mild to moderate coronary artery stenosis, we 
      decided to extend the ESCAPE study to investigate the long-term effect of 
      cilostazol and aspirin, named the ESCAPE-extension study. The study participants 
      had been investigated for cardiovascular events for up to 7 years, bringing the 
      total follow-up time to a median of 5.2 years (interquartile range 
      3.6-6.7 years). Adverse events were also investigated. RESULTS: Among 100 
      participants from the original study, 88 were included in this extension study. 
      Cilostazol treatment reduced the incidence of cardiovascular events in the 
      patients with T2DM when compared with aspirin for a 5.2-year median follow-up 
      (hazard ratio 0.24; 95% CI, 0.07-0.83). The cardiovascular benefit of cilostazol 
      therapy was maintained along with age, sex, systolic blood pressure, low-density 
      lipoprotein cholesterol, and coronary artery calcium score. No serious adverse 
      events in the cilostazol group were noted in the follow-up period. CONCLUSIONS: 
      In this ESCAPE-extension study, cilostazol treatment proved its efficacy in 
      reducing cardiovascular events compared with aspirin in diabetic patients with 
      subclinical coronary artery disease, suggesting the beneficial role of cilostazol 
      in the primary prevention of cardiovascular disease.
CI  - (c) 2022 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai 
      JiaoTong University School of Medicine and John Wiley & Sons Australia, Ltd.
FAU - Sohn, Minji
AU  - Sohn M
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, Republic of Korea.
FAU - Chun, Eun Ju
AU  - Chun EJ
AD  - Department of Radiology, Seoul National University Bundang Hospital, Seoul 
      National University College of Medicine, Seongnam, Republic of Korea.
FAU - Lim, Soo
AU  - Lim S
AUID- ORCID: 0000-0002-4137-1671
AD  - Department of Internal Medicine, Seoul National University Bundang Hospital, 
      Seoul National University College of Medicine, Seongnam, Republic of Korea.
LA  - eng
GR  - Korean Diabetes Association/
GR  - Otsuka Pharmaceutical/
GR  - Seoul National University Bundang Hospital/
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20220805
PL  - Australia
TA  - J Diabetes
JT  - Journal of diabetes
JID - 101504326
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - N7Z035406B (Cilostazol)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Aspirin/adverse effects/therapeutic use
MH  - Cilostazol/therapeutic use
MH  - *Coronary Artery Disease/etiology/prevention & control
MH  - *Coronary Stenosis/chemically induced/drug therapy
MH  - *Diabetes Mellitus, Type 2/chemically induced/complications/drug therapy
MH  - Drug Therapy, Combination
MH  - Follow-Up Studies
MH  - Humans
MH  - Platelet Aggregation Inhibitors/adverse effects
MH  - Treatment Outcome
PMC - PMC9426278
OTO - NOTNLM
OT  - cardiovascular diseases
OT  - diabetes mellitus
OT  - platelet aggregation inhibitors
OT  - type 2
OT  - 关键词:2型糖尿病
OT  - 动脉粥样硬化
OT  - 心血管疾病
OT  - 血小板聚集抑制剂
COIS- The authors have no conflicting interests relevant to this article to disclose.
EDAT- 2022/08/07 06:00
MHDA- 2022/09/02 06:00
PMCR- 2022/08/05
CRDT- 2022/08/06 03:02
PHST- 2022/06/27 00:00 [revised]
PHST- 2022/04/21 00:00 [received]
PHST- 2022/07/09 00:00 [accepted]
PHST- 2022/08/07 06:00 [pubmed]
PHST- 2022/09/02 06:00 [medline]
PHST- 2022/08/06 03:02 [entrez]
PHST- 2022/08/05 00:00 [pmc-release]
AID - JDB13300 [pii]
AID - 10.1111/1753-0407.13300 [doi]
PST - ppublish
SO  - J Diabetes. 2022 Aug;14(8):524-531. doi: 10.1111/1753-0407.13300. Epub 2022 Aug 
      5.